BeiGene ‘s Elliott Wave Correction Far From Over
BeiGene develops and commercializes oncology medicines globally. Like most other biotechnology companies, BGNE is not profitable. The stock’s value derives mainly from the market’s...
All from AMGEN
BeiGene ‘s Elliott Wave Correction Far From Over
BeiGene develops and commercializes oncology medicines globally. Like most other biotechnology companies, BGNE is not profitable. The stock’s value...
Amgen Stock in Trouble, Despite Strong Results
Amgen Inc. (NASDAQ:AMGN) reported its full year 2017 results on February 1st. On a non-GAAP basis, the California-based biotech giant earned $12.58 per share,...
Amgen Stock in Trouble, Despite Strong Results
Amgen Inc. (NASDAQ:AMGN) reported its full year 2017 results on February 1st. On a non-GAAP basis, the California-based biotech...
